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The article published by Wu et al. [1] in Journal of Breast Can-
cer proposed that the presence of so called ‘tumor stem cells’ 
may be an additional parameter to determine the extent of 
breast cancer invasion in the setting of surgery following neo-
adjuvant chemotherapy. However, this article has some note-
worthy concerns. The first one is regarding the concept of ‘tu-
mor stem cells’. The second is about the markers the author 
used in the article. The third is their way of determining the 
tumor margin. 
It seems that the authors are arguing CD44(+)CD24(-) cells 
as human breast ‘tumor stem cells.’ However, their argument 
is not so well accepted since the tumor stem cell is not a syn-
onym of a tumor-initiating cell. While several studies provid-
ed indirect evidence for the existence of mammary stem cells 
in human and in mice, these stem cells have not yet been pro-
spectively isolated at a single cell level in human breast cancer. 
According to the cancer stem cell model, the tumorigenic stem 
cells are maintained through self-renewal and have the ability 
to differentiate into non-tumorigenic cancer cells [2]. It has 
been postulated that the cancer stem cells are from the normal 
stem/progenitor cells as a result of accumulated mutation dur-
ing the self renewal process. However, a recent study suggests 
that this counterpart-relationship of the human breast epithe-
lial hierarchy is not necessary to develop a breast cancer; an 
aberrant luminal progenitor population is a target for trans-
formation in BRCA1-associated basal tumors [3]. Because a 
single tumor stem cell that can repopulate the heterogeneity 
of human breast cancer has not been identified yet, it has not 
been clear whether there is a certain specific ‘tumor stem cell’ 
or ‘tumor initiating cells’ which have tumorigenic capability. 
While the monumental report proposed that the CD44(+)
CD24(-/low) might be the characteristics of tumorigenic breast 
cancer cells, there still has been little consensus on the suitable 
markers for the breast cancer stem cells [4]. It is still not clear 
whether CD44(+)CD24(-) itself is true and definite character-
istics of human breast tumor stem cells or not. For example, 
aldehyde dehydrogenase (ALDH) was suggested as a useful 
marker for enriching tumor-initiating cells in immunodeficient 
mice [5,6]. CD44(+)CD24(-/low) subtype can be subdivided 
by ALDH1 biomarker, and interestingly, the overlap between 
CD44(+)CD24(-/low) and ALDH1 phenotypes in breast can-
cer seems to be very small [5,7]. Regarding the intrinsic molec-
ular subtypes, basal-like tumors contain a higher percentage of 
cells with CD44(+)CD24(-/low) and ALDH1-positive cells [7]. 
CD44(+)CD24(-/low) might be considered as the markers for 
basal subtypes rather than those of breast tumor-initiating cells, 
and CD44(+)CD24(-/low) alone cannot be considered as a 
definitive marker for stem cell characteristics. 
In this article, the authors also suggest that six categories can 
be classified from the pattern of cancer cells and stem cells, 
which are identified in the immunofluorescence studies per-
formed on tissue sections obtained from surgical resection of 
tumors following neoadjuvant chemotherapy. According to 
the presented methods, 0.5×0.5×0.5 cm
3 sized sections were 
obtained at 1 cm intervals from the tumor diameter up to 3 cm 
outside the maximum diameter of the tumor. We are seriously 
concerned whether it is a sound way to identify the border of 
breast cancer and remove a piece of tissue at 1 cm intervals in 
removed fresh breast specimen after neoadjuvant chemother-
apy with the naked eye. After neoadjuvant chemotherapy, the 
identification of patients with a pathologic complete response 
before surgery often becomes difficult by physical examination. 
Moreover, imaging studies such as mammography, ultrasonog-
raphy or magnetic resonance imaging cannot reliably assess 
degree of response. Neoadjuvant chemotherapy-induced tu-
mor regression is usually patchy, remaining islands of viable 
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tumor cells, and it is not concentric [8]. In case of the remained 
tumor nests after neoadjuvant chemotherapy, it can be hardly 
feasible to identify tumor margins with the naked eye. We are 
deeply apprehensive that this method may not be always pos-
sible and repeatedly performed in a standardized way. 
A breast cancer resistant to the chemotherapy or radiation 
may contain higher levels of CD44(+)CD24(-/low) cells [9]. 
However, this does not necessarily mean that ‘tumor stem cells’ 
are resistant to the chemotherapy or radiation because of the 
recent evidences that CD44(+)CD24(-/low) is not an absolute 
marker of breast cancer stem cells. This study is very interesting 
in trying to find a pattern between the distribution of CD44(+)
CD24(-/low) cells from the tumor margin. However, in our 
humble opinion, careful consideration should be given from 
the above viewpoints. 
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